Mary-EllenTaplinMD

Oncology • Boston, MA

Associate Professor of Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Taplin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Taplin's full profile

Already have an account?

Office
450 Brookline Ave
D1230
Boston, MA 02115
Phone+1 617-582-7221

Fax+1 617-632-2165

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1993
UMass Chan Medical SchoolResidency, Internal Medicine, 1986 - 1990
University of Massachusetts Medical SchoolClass of 1986

Certifications & Licensure

MA State Medical License 1987 - 2025
NH State Medical License 2023 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
Boston Magazine Castle Connolly, 2008-2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy Start of enrollment: 1997 Jan 01
Completed
A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer Start of enrollment: 2004 Jan 01
Completed
Phase 2
Mifepristone (RU-486) in Androgen Independent Prostate Cancer Start of enrollment: 2005 Feb 01
Completed
Phase 2
MRI-guided Bone Marrow Biopsies of Prostate Cancer Patients Start of enrollment: 2001 Jul 01
Completed
Not Applicable
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment Start of enrollment: 2004 Mar 01
Completed
Phase 2
Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy Start of enrollment: 2006 Jun 01
Completed
Phase 2
RAD001 and Bicalutamide for Androgen Independent Prostate Cancer Start of enrollment: 2008 Feb 01
Completed
Phase 2
Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer Start of enrollment: 2008 Jun 01
Completed
Phase 2
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy Start of enrollment: 2008 Oct 01
Completed
Phase 2
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer Start of enrollment: 2009 Oct 01
Completed
Phase 1
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy Start of enrollment: 2011 Jan 01
Completed
Phase 2
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole Start of enrollment: 2010 Dec 01
Withdrawn
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer Start of enrollment: 2011 Jul 01
Completed
Phase 1, Phase 2
Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer Start of enrollment: 2011 Sep 01
Completed
Phase 2
A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer Start of enrollment: 2012 Dec 01
Terminated
Phase 2
Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer Start of enrollment: 2013 Sep 13
Completed
Phase 2
Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer Start of enrollment: 2014 Jan 27
Active, not recruiting
Phase 2
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer Start of enrollment: 2014 Jun 01
Completed
Phase 2
Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone. Start of enrollment: 2015 May 01
Completed
Phase 2
Personal Web Page In Clinical Trial Participant Education Start of enrollment: 2014 Jul 21
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers.
Pedro C Barata, Kevin K Zarrabi, Axel Bex, Petros Grivas, Ken Hermann
European Urology. 2024-12-04
A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer.
Daniel Boiarsky, Alok K Tewari, Doga C Gulhan, Ziad Bakouny, Guruprasad Ananda
The Prostate. 2024-12-01
Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Confere...
Alan H Bryce, Neeraj Agarwal, Himisha Beltran, Maha H Hussain, Oliver Sartor
Cancer. 2024-12-01

Lectures

PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to ...
2019 ASCO Annual Meeting - 6/1/2019
Optimizing Androgen Receptor Targeting Strategies Perspective
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Other

Clinical presentation and diagnosis of prostate cancer
Taplin M, Smith JA, Kantoff PW
http://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-prostate-cancer
UpToDate, Wolters Kluwer Health - 2013-02-05
Initial staging and evaluation of men with newly diagnosed prostate cancer
Taplin M, Smith JA, Kantoff PW
http://www.uptodate.com/contents/initial-staging-and-evaluation-of-men-with-newly-diagnosed-prostate
UpToDate, Wolters Kluwer Health - 2013-02-05
Testicular sex cord stromal tumors
Taplin M
http://www.uptodate.com/contents/testicular-sex-cord-stromal-tumors
UpToDate, Wolters Kluwer Health - 2012-04-18

Authored Content

Clinical and Genomic Characterization of Low–Prostate-Specific Antigen, High-Grade Prostate CancerFebruary 2018

Press Mentions

Neoadjuvant NHAs Followed by Surgery Can Improve Key Outcomes in High-Risk Prostate Cancer PatientsSeptember 12th, 2022
The Prostate Cancer Foundation Announces First Ever Pcf-Pfizer Global Health Equity Challenge Award WinnersApril 29th, 2022
Rana R. McKay, MD: Developing Clinical Trials to Answer Questions Raised in PracticeApril 20th, 2022
Join now to see all